8-K: Allurion Relaunches Weight-Loss Balloon in France After Regulatory Clearance

Allurion Technologies announces the relaunch of its Allurion Balloon in France following clearance from the French regulatory authority, ANSM, and is considering clinical trials combining the balloon with GLP-1s.

Summary

• Allurion Technologies, Inc. is relaunching its Allurion Balloon in France after receiving clearance from the French regulatory authority, ANSM.
• France has historically been a top-performing market for Allurion, representing approximately 15% of their revenue.
• The company is exploring clinical trials in France to study the combination of the Allurion Balloon with GLP-1s to prevent muscle loss, a common side effect of GLP-1 therapies.
• A study of 571 patients showed that the Allurion Balloon resulted in a 5.6% gain in lean body mass while losing 14% of total body weight over four months.
• Another study of 167 patients showed a 15.7% weight reduction with no change in muscle mass using the Allurion Balloon.
• Allurion intends to initiate clinical trials to assess whether the Allurion Balloon combined with GLP-1s offers superior outcomes to GLP-1 therapies alone, focusing initially on muscle mass and later on dose reduction of GLP-1s to reduce side effects.

Sentiment

Score: 8

Explanation: The document is positive due to the regulatory clearance in France and the potential for combination therapies with GLP-1s to address muscle loss. The company is also planning future clinical trials.

Positives

• Regulatory clearance in France allows Allurion to resume sales of the Allurion Balloon in a historically strong market.
• The potential combination therapy of the Allurion Balloon and GLP-1s could address a significant side effect of GLP-1s (muscle loss).
• Clinical studies have demonstrated positive outcomes with the Allurion Balloon, including weight loss and maintenance or increase in muscle mass.
• The company is exploring clinical trials focused on dose reduction of GLP-1s as a means to reduce side effects and increase adherence.

Risks

• The forward-looking statements are subject to risks and uncertainties, including regulatory approval, commercialization success, clinical trial outcomes, market evolution, intellectual property protection, and economic downturns.
• The company's performance is subject to the risks and uncertainties described in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC.

Future Outlook

Allurion plans to initiate clinical trials to assess the combination of the Allurion Program and GLP-1s, and expects to announce other clinical trials in the future that will study dose reduction of GLP-1s as a means to reduce side effects and increase adherence.

Management Comments

• 'We are thrilled the Allurion Balloon will once again serve French patients as a clinically proven treatment for obesity,' said Dr. Shantanu Gaur, Founder and CEO of Allurion.
• 'Historically, France has been our top performing market representing approximately 15% of our revenue, and we are looking forward to ramping back up in the coming quarters,' said Dr. Shantanu Gaur, Founder and CEO of Allurion.
• 'We intend to initiate clinical trials designed to assess whether the Allurion Balloon combined with GLP-1s offers superior outcomes to GLP-1 therapies alone,' said Dr. Shantanu Gaur.

Industry Context

The announcement comes as GLP-1 drugs are gaining popularity for weight loss, but are associated with muscle loss, creating an opportunity for Allurion to explore combination therapies.

Comparison to Industry Standards

• The document references studies on GLP-1 therapies, such as Wilding et al. NEJM. 2021, which demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.
• The Allurion Balloon studies (Dejeu et al. Clin. Pract. 2024) show contrasting results, with patients either maintaining or increasing muscle mass while losing weight, potentially offering a competitive advantage over GLP-1 therapies alone.

Stakeholder Impact

• Shareholders: Positive news due to market expansion and potential for increased revenue.
• Patients: Access to a clinically proven treatment for obesity in France.
• Healthcare providers: Potential for a new combination therapy to address muscle loss associated with GLP-1s.

Next Steps

• Ramping up sales of the Allurion Balloon in France.
• Initiating clinical trials to assess the combination of the Allurion Balloon and GLP-1s.
• Announcing other clinical trials in the future that will study dose reduction of GLP-1s.

Key Dates

Keywords

Allurion Balloon, GLP-1s, Obesity, Weight Loss, France, Clinical Trials, Muscle Mass, ANSM, Regulatory Clearance